Description
Testosterone Undecanoate is the longest-acting of common test esters, formed by esterification at the 17β-hydroxyl with undecanoic acid. The eleven-carbon side chain makes the compound extremely lipophilic and is therefore released via the intestinal lymphatic pathway (oral form) or very slowly from the intramuscular depot.
Per study reports the IM elimination half-life is about 20.9 days in tea seed oil, and 33.9 days in castor oil. This makes Undecanoate the only test ester that works clinically with 10-14 week injection intervals. The long intervals produce a remarkably smooth plasma level profile without the typical roller-coaster effects of shorter esters.
Pharmacokinetic studies show that Undecanoate tends to control aromatization to estradiol better through the lower peak values than high-dose short-acting esters. Compared to transdermal gel formulations, IM Undecanoate delivers more stable steady-state concentrations.
In TRT research literature Undecanoate is considered the gold standard for patients with adherence issues or who prefer low injection frequency. In bodybuilding research the substance is less common because the long half-life makes mid-protocol adjustments nearly impossible.
You can order Testosterone Undecanoate as an oily injection solution in 10-vial packs at 300mg/ml.
This information is for research and educational purposes only. No medical recommendations.
Risks & Safety
Testosterone Undecanoate shares the risk profile of all testosterone esters - the lower peak values tend to control aromatization better, but the long half-life makes clearance take months if side effects occur.
Documented in studies and the application literature:
- Estrogen conversion: testosterone aromatizes to estradiol. Through the lower peak values the E2 rise tends to be more controllable in studies than with short-acting esters, yet water retention and blood pressure rise are documented.
- Suppression of endogenous production: exogenous testosterone throttles the body’s own production via the HPTA axis. Testicular atrophy and reduced fertility are documented, recovery after discontinuation is not guaranteed.
- Cardiovascular: studies describe unfavorable shifts in the lipid profile (HDL falls), elevated hematocrit and an associated thrombosis risk.
- Long half-life as a risk: if side effects occur, the compound cannot be quickly dialed back because of the 20-34 day half-life, and clearance takes months.
Baseline bloodwork before, during and after a research protocol is strongly advised. This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- Intramuscular Testosterone Undecanoate: Pharmacokinetic Aspects of a Novel Testosterone Formulation during Long-Term Treatment of Men with Hypogonadism - The Journal of Clinical Endocrinology and Metabolism 2004, Schubert et al: Investigates the long-term pharmacokinetics of intramuscular Undecanoate in 40 men - documents the smooth plasma profile across the long injection intervals.
- Pharmacokinetics and Safety of Long-Acting Testosterone Undecanoate Injections in Hypogonadal Men: An 84-Week Phase III Clinical Trial - Journal of Andrology 2010, Wang et al: 84-week study - steady state is reached after the third injection.
- Comparative pharmacokinetics of testosterone esters - Testosterone (Springer) 1998, Behre & Nieschlag: Places Undecanoate as the longest test ester within the comparison of ester half-lives.
- Pharmacokinetics of testosterone therapies in relation to diurnal variation of serum testosterone levels as men age - Andrology 2021, Pastuszak et al: Review of the pharmacokinetics of testosterone delivery forms including the long-acting esters.
- Pharmacology of testosterone replacement therapy preparations - Translational Andrology and Urology 2016, Shoskes et al: Comparative pharmacokinetics with particular focus on the long-acting esters.
